Literature DB >> 20078325

Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission.

Hagop M Kantarjian1, Deborah Thomas, Farhad Ravandi, Stefan Faderl, Guillermo Garcia-Manero, Jianquin Shan, Sherry Pierce, Jorge Cortes, Susan O'Brien.   

Abstract

The outcome of adults with acute lymphocytic leukemia (ALL) who achieve a complete response (CR) on salvage therapy is thought to be poor, but not previously analyzed. To define the course of adult ALL post CR on salvage therapy and the effects of pretreatment factors on prognosis. One hundred seventy-two adults with ALL who achieved a second or third CR on salvage therapy were reviewed. Prognostic factors affecting survival were analyzed by multivariate analysis. The median survival post achieving CR for the entire group was 10 months. The estimated 1-year survival rate was 42%. Forty-three patients underwent stem cell transplant in subsequent CR: their median survival was 12 months and the 3-year survival rate was 25%. Independent poor prognostic factors for survival were age  > 55 years, duration of first CR < 12 months, and lactate dehydrogenase levels > 1000 IU/L. This analysis defines the outcome of adult ALL in CR post salvage therapy and the prognostic factors influencing survival. These results could be used in assessing the efficacy of new treatments aimed at improving CR durations and survival post salvage therapy.

Entities:  

Mesh:

Year:  2010        PMID: 20078325      PMCID: PMC4086446          DOI: 10.3109/10428190903503412

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  16 in total

Review 1.  Salvage therapy for refractory or relapsed acute lymphocytic leukemia.

Authors:  G Garcia-Manero; D A Thomas
Journal:  Hematol Oncol Clin North Am       Date:  2001-02       Impact factor: 3.722

Review 2.  Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL).

Authors:  N Gökbuget; D Hoelzer; R Arnold; A Böhme; C R Bartram; M Freund; A Ganser; M Kneba; W Langer; T Lipp; W D Ludwig; G Maschmeyer; H Rieder; E Thiel; A Weiss; D Messerer
Journal:  Hematol Oncol Clin North Am       Date:  2000-12       Impact factor: 3.722

Review 3.  Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87.

Authors:  A Thiebaut; J P Vernant; L Degos; F R Huguet; J Reiffers; C Sebban; E Lepage; X Thomas; D Fière
Journal:  Hematol Oncol Clin North Am       Date:  2000-12       Impact factor: 3.722

Review 4.  Acute lymphoblastic leukemia.

Authors:  C H Pui; W E Evans
Journal:  N Engl J Med       Date:  1998-08-27       Impact factor: 91.245

5.  Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy.

Authors:  D A Thomas; H Kantarjian; T L Smith; C Koller; J Cortes; S O'Brien; F J Giles; J Gajewski; S Pierce; M J Keating
Journal:  Cancer       Date:  1999-10-01       Impact factor: 6.860

Review 6.  Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B.

Authors:  R A Larson
Journal:  Hematol Oncol Clin North Am       Date:  2000-12       Impact factor: 3.722

Review 7.  The Medical Research Council trials in adult acute lymphocytic leukemia.

Authors:  I J Durrant; S M Richards; H G Prentice; A H Goldstone
Journal:  Hematol Oncol Clin North Am       Date:  2000-12       Impact factor: 3.722

8.  Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia.

Authors:  Sima Jeha; Varsha Gandhi; Ka Wah Chan; Lisa McDonald; Irma Ramirez; Renee Madden; Michael Rytting; Mark Brandt; Michael Keating; William Plunkett; Hagop Kantarjian
Journal:  Blood       Date:  2003-10-09       Impact factor: 22.113

9.  A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.

Authors:  Oliver G Ottmann; Brian J Druker; Charles L Sawyers; John M Goldman; Jose Reiffers; Richard T Silver; Sante Tura; Thomas Fischer; Michael W Deininger; Charles A Schiffer; Michele Baccarani; Alois Gratwohl; Andreas Hochhaus; Dieter Hoelzer; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Stephen G O'Brien
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

10.  Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.

Authors:  J B Nachman; H N Sather; M G Sensel; M E Trigg; J M Cherlow; J N Lukens; L Wolff; F M Uckun; P S Gaynon
Journal:  N Engl J Med       Date:  1998-06-04       Impact factor: 91.245

View more
  5 in total

1.  Allogeneic stem cell transplantation for adult acute lymphoblastic leukemia: when and how.

Authors:  Josep-Maria Ribera
Journal:  Haematologica       Date:  2011-08       Impact factor: 9.941

2.  A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies.

Authors:  Maksim Mamonkin; Rayne H Rouce; Haruko Tashiro; Malcolm K Brenner
Journal:  Blood       Date:  2015-06-08       Impact factor: 22.113

3.  Prediction model for mortality after intracranial hemorrhage in patients with leukemia.

Authors:  Farshid Dayyani; Sarah Schellhorn Mougalian; Kiran Naqvi; Jianqin Shan; Farhad Ravandi; Jorge Cortes; Jeffrey Weinberg; Elias Jabbour; Stefan Faderl; William Wierda; Deborah Thomas; Susan O'Brien; Sherry Pierce; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Am J Hematol       Date:  2011-04-20       Impact factor: 10.047

Review 4.  Novel immunotherapies in lymphoid malignancies.

Authors:  Connie Lee Batlevi; Eri Matsuki; Renier J Brentjens; Anas Younes
Journal:  Nat Rev Clin Oncol       Date:  2015-11-03       Impact factor: 66.675

5.  Management and treatment of relapsed or refractory Ph(-) B-precursor ALL: a web-based, double-blind survey of EU clinicians.

Authors:  Deborah Saltman; Arie Barlev; Divyagiri Seshagiri; Ioannis Katsoulis; Vincent Lin; Beth Barber
Journal:  BMC Cancer       Date:  2015-10-24       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.